EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Ring Chromosomes in Patients with Myeloid Neoplasms are Associated with a Poor Response to Therapy

Daniel I Nathan, Ronald Hoffman, Daiva Ahire, John Mascarenhas, Bridget K Marcellino, Douglas Tremblay, Lewis R Silverman, Vesna Najfeld, Jonathan Feld

Acta Haematologica · 2025

DOI: 10.1159/000546757 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Haematologica, 2025. Verfasst von Daniel I Nathan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Tisch Cancer Institute, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA, daniel.nathan@…. Hauptthemen laut MEDLINE: Ring Chromosomes, Myeloproliferative Disorders, Myelodysplastic Syndromes. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Ring chromosomes (RC) are acquired circular structural abnormalities associated with gain or loss of genetic material, which are thought to be associated with inferior outcomes of patients with myeloid neoplasms (MN). The responses of patients with MN and RC to the standard therapeutic options have not been reported previously.

Methods

We analyzed the demographics and outcomes of 31 consecutive patients with MN and RC and compared median overall survival (mOS) and progression-free survival (PFS) of patients who received supportive care (n = 9), cytotoxic chemotherapeutic options (n = 3), hypomethylating agents (HMA) alone (n = 6), or HMA in combination with venetoclax (n = 13).

Results

Over 60% of all patients with RC had either a TP53 mutation, loss of 17p, or both. Interestingly, 22/31 (71%) of patients did not receive prior radiation or chemotherapy. Patients who received supportive care had a shorter mOS (p = 0.001), but none of the therapeutic interventions were associated with further improvement in prolonging mOS (p = 0.86) or PFS. The presence of a complex karyotype, TP53 mutations/loss of TP53, or a treatment-related MN was not independently associated with an inferior OS in MN patients with RC.

Conclusion

These findings indicate the patients with MN and RC have especially poor outcomes, and that effective treatment strategies remain an unmet need.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ring ChromosomesMyeloproliferative DisordersMyelodysplastic SyndromesHumansFemaleAgedMaleMiddle AgedAged, 80 and overTumor Suppressor Protein p53MutationAdult

Stichwörter der Autor:innen

Acute myeloid leukemiaHypomethylating agentMyelodysplastic syndromesMyeloid malignancyMyeloproliferative neoplasmsRing chromosomesVenetoclax

Substanzen

Tumor Suppressor Protein p53

Autor:innen und Institutionen

  • Tisch Cancer Institute, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA, daniel.nathan@mssm.edu.
  • Tisch Cancer Institute, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Nathan, D. I., Hoffman, R., Ahire, D., Mascarenhas, J., Marcellino, B. K., Tremblay, D., Silverman, L. R., Najfeld, V., & Feld, J. (2025). Ring Chromosomes in Patients with Myeloid Neoplasms are Associated with a Poor Response to Therapy. Acta Haematologica. https://doi.org/10.1159/000546757

Vancouver

Nathan DI, Hoffman R, Ahire D, Mascarenhas J, Marcellino BK, Tremblay D, et al. Ring Chromosomes in Patients with Myeloid Neoplasms are Associated with a Poor Response to Therapy. Acta Haematologica. 2025. doi:10.1159/000546757

BibTeX
@article{Nathan2025,
  author = {Nathan, Daniel I and Hoffman, Ronald and Ahire, Daiva and Mascarenhas, John and Marcellino, Bridget K and Tremblay, Douglas and Silverman, Lewis R and Najfeld, Vesna and Feld, Jonathan},
  title = {Ring Chromosomes in Patients with Myeloid Neoplasms are Associated with a Poor Response to Therapy},
  journal = {Acta Haematologica},
  year = {2025},
  doi = {10.1159/000546757}
}
Kostenlos starten →